Immune responses to injury and their links to eye disease.
Stepp MA, Menko AS.
Transl Res. 2021 Oct;236:52-71. doi: 10.1016/j.trsl.2021.05.005. Epub 2021 May 27.
Multi-omics profiling of retinal pigment epithelium reveals enhancer-driven activation of RANK-NFATc1 signaling in traumatic proliferative vitreoretinopathy.
Liao M, Zhu X, Lu Y, Yi X, Hu Y, Zhao Y, Ye Z, Guo X, Liang M, Jin X, Zhang H, Wang X, Zhao Z, Chen Y, Yan H.
Nat Commun. 2024 Aug 25;15(1):7324. doi: 10.1038/s41467-024-51624-y.
Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.
Khanum BNMK, Guha R, Sur VP, Nandi S, Basak SK, Konar A, Hazra S.
Eye (Lond). 2017 Sep;31(9):1317-1328. doi: 10.1038/eye.2017.21. Epub 2017 Mar 17.
TRAUMATIC PROLIFERATIVE VITREORETINOPATHY: Clinical and Histopathological Observations.
Jin Y, Chen H, Xu X, Hu Y, Wang C, Ma Z.
Retina. 2017 Jul;37(7):1236-1245. doi: 10.1097/IAE.0000000000001350.
ABCA4 mediated traumatic proliferative vitreoretinopathy associated with PI3K/Akt signaling pathway.
Menghua W, Hu Z.
Heliyon. 2024 Mar 12;10(7):e27024. doi: 10.1016/j.heliyon.2024.e27024. eCollection 2024 Apr 15.
Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy.
Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, Varinli S.
Ocul Immunol Inflamm. 2005 Sep-Oct;13(5):375-81. doi: 10.1080/09273940490518900.
Vitreous Olink proteomics reveals inflammatory biomarkers for diagnosis and prognosis of traumatic proliferative vitreoretinopathy.
Guo H, Wang T, Yu J, Shi Z, Liang M, Chen S, He T, Yan H.
Front Immunol. 2024 Feb 22;15:1355314. doi: 10.3389/fimmu.2024.1355314. eCollection 2024.
A COMPARATIVE ANALYSIS OF TRAUMATIC RETINAL DETACHMENT AFTER OPEN AND CLOSED GLOBE INJURIES IN CHILDREN.
Wenzel DA, Gassel CJ, Druchkiv V, Neubauer J, Bartz-Schmidt KU, Dimopoulos S.
Retina. 2024 Aug 1;44(8):1422-1430. doi: 10.1097/IAE.0000000000004120.
Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations.
Esser P, Heimann K, Wiedemann P.
Br J Ophthalmol. 1993 Nov;77(11):731-3. doi: 10.1136/bjo.77.11.731.
Idelalisib inhibits experimental proliferative vitroretinopathy.
Dong L, Han H, Huang X, Ma G, Fang D, Qi H, Han Z, Wang L, Tian J, Vanhaesebroeck B, Zhang G, Zhang S, Lei H.
Lab Invest. 2022 Dec;102(12):1296-1303. doi: 10.1038/s41374-022-00822-7. Epub 2022 Jul 19.
